{
    "clinical_study": {
        "@rank": "168198", 
        "arm_group": [
            {
                "arm_group_label": "AM001", 
                "arm_group_type": "Experimental", 
                "description": "AM001 Cream, 7.5%. 2x daily for 12 weeks."
            }, 
            {
                "arm_group_label": "Vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo of AM001 Cream. 2x daily for 12 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the safety and efficacy profile of AM001 Cream and its vehicle in the treatment\n      of plaque psoriasis."
        }, 
        "brief_title": "Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Plaque Psoriasis", 
            "Skin Diseases, Papulosquamous", 
            "Skin Diseases"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Psoriasis", 
                "Skin Diseases", 
                "Skin Diseases, Papulosquamous"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subjects must provide Institutional Review Board (IRB) approved written informed\n             consent.\n\n          2. Subjects must be male or female, at least 18 years of age.\n\n          3. Subjects with a definite diagnosis of plaque psoriasis that is clinically active (for\n             at least 3 months), involving at least 3% and up to 20% of the body surface area (not\n             including the scalp, face, hands, feet, and intertriginous areas).\n\n          4. Subjects with an Investigator's Global Assessment (IGA) of disease severity of at\n             least moderate severity (score \u2265 3) as an overall assessment.\n\n          5. Subjects with a minimum plaque elevation of at least moderate severity (PASI grade \u2265\n             3) at the target lesion site.\n\n          6. If females of childbearing potential, the subject must have a negative urine\n             pregnancy test, and must have been using an acceptable form of birth control for at\n             least two months prior to Screening and are willing to continue birth control\n             throughout the study.\n\n          7. Subjects must be willing and able to understand and comply with the requirements of\n             the study, apply the study medication as instructed, return for the required\n             treatment period visits, comply with therapy prohibitions, and be able to complete\n             the study.\n\n          8. Subjects must be in good health, as confirmed by medical history and physical exam,\n             and free from any clinically significant disease/condition, other than plaque\n             psoriasis, that might interfere with the study evaluations.\n\n          9. Subjects must be willing to limit sun exposure overall. Subjects are prohibited from\n             sunbathing or intentional tanning or intense sun exposure including the use of\n             tanning booths/lights or other artificial UV light sources throughout the study.\n\n        Exclusion Criteria:\n\n          1. Female subjects who are pregnant, nursing, or planning a pregnancy within the study\n             participation period.\n\n          2. Subjects who have a current diagnosis of guttate, pustular, inverse, exfoliative, or\n             erythrodermic psoriasis.\n\n          3. Subjects who have a history of psoriasis unresponsive to topical treatments.\n\n          4. Subjects who have a history of a disorder that may interfere with the evaluation of\n             plaque psoriasis (e.g., atopic dermatitis, contact dermatitis, tinea corporis,\n             cutaneous lymphoma, etc.).\n\n          5. Presence of pigmentation, extensive scarring, or pigmented lesions in the treatment\n             areas, which could interfere with the rating of efficacy parameters.\n\n          6. Subjects with unstable medical disorders, life-threatening disease, or current\n             malignancies.\n\n          7. Subjects with clinically significant ECG or laboratory abnormalities at Screening (as\n             determined by the Investigator).\n\n          8. Subjects who are immunosuppressed.\n\n          9. Subjects who have a history of allergy or a known hypersensitivity to any component\n             of the study medication.\n\n         10. Subjects who have been treated with any systemic steroids within the 4 weeks prior to\n             the study entry.\n\n         11. Subjects who have been treated with systemic or photo antipsoriatic therapies/drugs\n             within 4 weeks prior to study entry including methotrexate, cyclosporine, acitretin\n             and other oral retinoids, broadband or narrowband UVB, PUVA, home or professional\n             tanning lights or other nonprescription UV light sources, photodynamic therapy (PDT),\n             lasers, mycophenalate mofetil (MMF), thioguanine, hydroxyurea, sirolimus,\n             azathioprine, 6-mercaptopurine (6-MP), or etanercept.\n\n         12. Subjects who have been treated with biologic therapy other than etanercept within 8\n             weeks prior to study entry. Vaccines will not be considered an exclusionary biologic\n             treatment.\n\n         13. Subjects who have been treated with any topical anti-psoriatic (e.g., salicylic acid,\n             anthralin, tar, etc.,) any topical corticosteroid medications, topical retinoids\n             (e.g., tazarotene, tretinoin), topical Vitamin D analogs (e.g., calcipotriene),\n             topical immunosuppressants (e.g., tacrolimus, pimecrolimus) within 2 weeks prior to\n             study entry.\n\n         14. Subjects who have been treated with lithium, antimalarial agents, or quinidine within\n             the 4 weeks prior to study entry.\n\n         15. Subjects who have received radiation therapy and/or anti-neoplastic agents, or taken\n             any immunosuppressant medication within 3 months prior to study entry."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01938599", 
            "org_study_id": "AD-AM001-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "AM001", 
                "description": "Cream, 2x daily for 12 weeks", 
                "intervention_name": "AM001 Cream, 7.5%", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "description": "Cream, 2x daily for 12 weeks", 
                "intervention_name": "Placebo of AM001 Cream", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Plaque Psoriasis", 
        "lastchanged_date": "September 5, 2013", 
        "location": [
            {
                "contact": {
                    "email": "fazevedo@intldermresearch.com", 
                    "last_name": "Fabio Azevedo", 
                    "phone": "305-225-0400"
                }, 
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33144"
                    }, 
                    "name": "International Dermatology Research, Inc."
                }, 
                "investigator": {
                    "last_name": "Javier Alonso-Llamazares, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dsnow@associatedskincare.com", 
                    "last_name": "Dawn Snow", 
                    "phone": "763-571-4200"
                }, 
                "facility": {
                    "address": {
                        "city": "Fridley", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55432"
                    }, 
                    "name": "Minnesota Clinical Study Center"
                }, 
                "investigator": {
                    "last_name": "Steven Kempers, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "abucko@abqdermtrials.com", 
                    "last_name": "Alicia Bucko, DO", 
                    "phone": "505-247-4220"
                }, 
                "facility": {
                    "address": {
                        "city": "Albuquerque", 
                        "country": "United States", 
                        "state": "New Mexico", 
                        "zip": "87106"
                    }, 
                    "name": "Academic Dermatology Association"
                }, 
                "investigator": {
                    "last_name": "Eduardo Tschen, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "zdraelos@northstate.net", 
                    "last_name": "Zoe Draelos, MD", 
                    "phone": "336-841-2040"
                }, 
                "facility": {
                    "address": {
                        "city": "High Point", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27262"
                    }, 
                    "name": "Dermatology Consulting Services"
                }, 
                "investigator": {
                    "last_name": "Zoe Draelos, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jscott@js-studies.com", 
                    "last_name": "Jeremy Scott, BBA", 
                    "phone": "979-774-5933"
                }, 
                "facility": {
                    "address": {
                        "city": "College Station", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77845"
                    }, 
                    "name": "J & S Studies"
                }, 
                "investigator": {
                    "last_name": "Terry Jones, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis", 
        "overall_contact": {
            "email": "toddk@amneal.com", 
            "last_name": "W. Todd Kays, Ph.D.", 
            "phone": "631-952-0214", 
            "phone_ext": "183"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "An overall assessment of disease severity will be performed at each study visit.", 
            "measure": "Investigator's Global Assessment of Disease Severity (IGA)", 
            "safety_issue": "No", 
            "time_frame": "Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01938599"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Erythema, Scaling and Plaque Elevation of the target lesion will be scored at baseline and at each subsequent study visit.", 
                "measure": "Target Lesion Psoriasis Area Severity Index (PASI)", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "description": "The % BSA of all treatable psoriatic lesions and regions will be recorded at baseline and at week 12.", 
                "measure": "Body Surface Area (BSA)", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "description": "The target lesion area will be measured at baseline and each-post-baseline visit.", 
                "measure": "Target Lesion Area", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "description": "Measured at baseline and week 12.", 
                "measure": "Dermatology Life Quality Index (DLQI)", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "description": "Systemic absorption will be determined in a subgroup.", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "Yes", 
                "time_frame": "2 Weeks"
            }
        ], 
        "source": "AmDerma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AmDerma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}